| ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES |
8. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consisted of the following as of the periods indicated: | | | September 30, | | | December 31, | | | | | 2026 | | | 2025 | | | Accrued research and development expense (1) | | $ | 1,741,083 | | | $ | 1,754,083 | | | Accrued directors and officers (owners) compensation | | | 1,373,491 | | | | 1,358,293 | | | Cash portion of the Lind Note repayments (2) | | | 625,000 | | | | 492,376 | | | Accrued compensation and employee benefits | | | 15,559 | | | | 86,744 | | | Others | | | 778,839 | | | | 470,133 | | | Total | | $ | 4,533,972 | | | $ | 4,161,629 | | | (1) | Management continually reviews the stage of clinical trial activity with the finance and clinical operations teams based on latest trial enrollment status, activity logs and vendor invoicing schedules, and then accrues expenses as incurred for services received or performed as of each balance sheet date. To date, there have been no material differences between management estimates of such expenses and the amounts incurred. | | | As of September 30, 2026, the $1,741,083 accrued research and development expense represents the amounts due to third-parties for outside contracted services for manufacturing and process development. According to periodic management review, during the nine months ended September 30, 2026, there were no significant changes in the stage of clinical trial activities, nor any new vendors added or modifications to contractual terms that would necessitate adjusting the accruals. Based on known information, current progress and services received as of September 30, 2026, it is very likely that the current estimate will not change to a significant extent. | However, the accruals may increase for additional services received in the future with the planned resumption of ophthalmology and CNS trials, or if new clinical trials are initiated. Actual results may differ materially from the current estimated amounts if there are unforeseen changes in trial progress, vendor performance, or billing practices in the future. | (2) | On October 26, 2026, the Company entered into a release and settlement agreement (the “Settlement Agreement”) with Lind. to settle $500,000 outstanding since April 2025. Pursuant to the Settlement Agreement, the Company shall pay Lind $625,000 (the “Settlement Payment”) and upon Lind’s receipt thereof, the Lind Notes shall be deemed paid and satisfied in full, cancelled and of no further force or effect and all liens, security interest and related security agreements and guaranteed under the Lind Transaction Documents shall automatically terminate and be released. This payable due to Lind was repaid upon fund distribution in Oct 30, 2026. Additionally, the Lind Warrant will increase by 20% (such shares of common stock are referred to herein as the “Warrant Shares”), with a result of Lind holding 477,600 warrants. |
|